David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug popularity and research into Alzheimer's.

Eli Lilly CEO David Ricks, also an Adobe director, paid $1 million on Jan. 28 for 2,250 shares of the software company. Bill Gates Says He Donated $100 Billion Of His Wealth To Charitable Causes ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks that Jim Cramer discussed. In the episode of CNBC's Squawk on the Street ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before ...

“It’s early days on a very, very large opportunity. There’s turbulence. I’ll own that,” Eli Lilly CEO David Ricks told investors during a call on Thursday when asked if the company is ...

Here's the Best of the Bunch. Elon Musk Clashes With CEO Of $1.7 Trillion Norway Wealth Fund And Tesla Shareholder Who Voted Against His $56 Billion Compensation Deal Mark Cuban Says If You Want ...

Eli Lilly ( LLY -3.00%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts ...

"2024 was a highly successful year for Lilly," said Eli Lilly CEO David Ricks in a statement. In addition to success with its weight-loss drugs, Ricks cited "major data readouts for tirzepatide in ...